POLY
MOLECULAR TARGETPoly [ADP-ribose] polymerase 1 (human)
POLY (Poly [ADP-ribose] polymerase 1 (human)) is targeted by 14 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting POLY
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Bortezomib | 0.69 | 1 |
| 2 | Camptothecin | 0.69 | 1 |
| 3 | Clofarabine | 0.69 | 1 |
| 4 | Daunorubicin | 0.69 | 1 |
| 5 | Demecolcine | 0.69 | 1 |
| 6 | Epirubicin | 0.69 | 1 |
| 7 | Gemcitabine | 0.69 | 1 |
| 8 | Homoharringtonine Semisynthetic derivative of harringtonine that acts as | 0.69 | 1 |
| 9 | Irinotecan | 0.69 | 1 |
| 10 | Nocodazole Nocodazole is | 0.69 | 1 |
| 11 | Podophyllotoxin | 0.69 | 1 |
| 12 | Teniposide | 0.69 | 1 |
| 13 | Thapsigargin | 0.69 | 1 |
| 14 | Trabectedin | 0.69 | 1 |
About POLY as a Drug Target
POLY (Poly [ADP-ribose] polymerase 1 (human)) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 14 compounds with documented POLY interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
POLY inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.